Answers are grounded in this paper and cite their sources.
Growth hormone (GH) is a potent anabolic hormone, and its clinical use has been extended to the improvement of metabolic imbalance in many disease,s including autoimmune disorders treated with glucocorticoids (GCs). GH has, however, a potential action on the immune system, and this might be a demerit in GH therapy for those diseases. We report here the anti‐GC effects of GH on T lymphocytes. Human peripheral T lymphocytes (HPTLs) expressed GH receptor mRNA. GH stimulated tyrosine phosphorylation of cellular proteins, including JAK2 and STAT5b in HPTLs. GH and IGF‐I alleviated dexamethasone (Dex)‐induced suppression of [ 3 H]thymidine incorporation into HPTLs. GH alleviated Dex‐induced apoptosis in CD4 + (positive) HPTLs. GH increased Bcl‐2 expression in CD4 + HPTLs but not in CD8 + HPTLs. In vivo, GH raised the CD4/8 ratio of T lymphocytes in rats chronically administered with Dex. These findings indicate that GH may inhibit GC‐induced apoptosis predominantly in CD4 + T lymphocytes and present important implications of GH therapy, especially for autoimmune disorders treated with GCs.
No takes yet. Share an insight, caveat, or question.
Dobashi et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: